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Phosphatase and tensin homologue (PTEN) is a critical cell endogenous inhibitor of phosphoinositide signaling in mammalian
cells. PTEN dephosphorylates phosphoinositide trisphosphate (PIP
3
), and by so doing PTEN has the function of negative
regulation of Akt, thereby inhibiting this key intracellular signal transduction pathway. In numerous cell types, PTEN loss-of-
function mutations result in unopposed Akt signaling, producing numerous effects on cells. Numerous reports exist regarding
mutations in PTEN leading to unregulated Akt and human disease, most notably cancer. However, less is commonly known
about nonmutational regulation of PTEN. This review focuses on an emerging literature on the regulation of PTEN at
the transcriptional, posttranscriptional, translational, and posttranslational levels. Specifically, a focus is placed on the role
developmental signaling pathways play in PTEN regulation; this includes insulin-like growth factor, NOTCH, transforming growth
factor, bone morphogenetic protein, wnt, and hedgehog signaling. The regulation of PTEN by developmental mediators affects
critical biological processes including neuronal and organ development, stem cell maintenance, cell cycle regulation, inflammation,
response to hypoxia, repair and recovery, and cell death and survival. Perturbations of PTEN regulation consequently lead to human
diseases such as cancer, chronic inflammatory syndromes, developmental abnormalities, diabetes, and neurodegeneration.
1. Introduction
Phosphatase and tensin homolog (PTEN) is a ubiqui-
tously expressed protein that functions as a phosphatase to
dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate
(PtdIns(3,4,5)P
3
or PIP
3
) by catalyzing the dephosphoryla-
tion of the 3󸀠 phosphate of the inositol ring in PIP
3
[1]. The
resulting product of this reaction is the biphosphate product
PIP
2
(PtdIns(4,5)P
2
). Since PIP
3
is a primary activator of
the signaling intermediate Akt, dephosphorylation of PIP
3
by PTEN results in inhibition of the AKT signaling pathway.
Akt is a serine/threonine-specific protein kinase that is
critical for many cellular functions including cell prolifera-
tion, apoptosis, transcription, and cell migration and struc-
ture [1]. PTEN also functions as a protein phosphatase by
dephosphorylating proteins including focal adhesion kinase
in the cytosol and Erk, histone H1, RAD51, and CENC-P in
the nucleus. Therefore, PTEN has effects on cell migration
via integrin signaling, chromatin remodeling through its
interactions with histones, cell cycle progression and arrest
independent of Akt signaling, DNA repair via its modulation
of RAD51, and centrosome stability via its role with CENC-
P. PTEN’s structure, described in Figure 1, consists of a
phosphatase domain harboring the active site and enzymatic
function of the protein and a C2 domain responsible for the
phospholipid membrane binding site [2]. As such, the C2
domain is responsible for cellular location and allows PTEN
localization tomembrane-bound PIP
3
; this promotes PTEN’s
phosphoinositide phosphatase function by locating it to the
cellular location of its substrates [2]. The functions of the C-
terminal and PDZ domains are less defined [2].
Because the downstream signaling pathways that PTEN
effects modulate very diverse and dynamic cellular func-
tions, PTEN is responsible for regulating the signals of
an abundance of mediators including cytokines, growth
factors, integrins, and autacoid ligands of G-protein-coupled
receptors [3–5]. The cellular mechanistic effects of PTEN
function and intrinsic Akt inhibition include modulation
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Figure 1: Protein domains of PTEN. PTEN has five distinct domains, consisting of an N-terminal PIP binding domain, the phosphatase
domain responsible for its enzymatic activity and containing acetylation sites responsible for regulating this phosphatase activity, the
regulatory C2 domain responsible for its cellular location and protein-protein interactions including those that modify enzyme activity or
localization, the less understood C-tail containing phosphorylation sites thought to be critical for PTEN’s stability, and finally the C-terminal
PDZ domain.
of many pathways; this includes cell cycle progression via
p27Kip1 [6], Wee1, p21, and cyclin D [7]; mTOR-mediated
cellular signaling [8]; apoptosis and survival effects mediated
by Bim [9], MDM2-p53 [10], Bcl-2, and Bax [11]; cellular
structure regulation mediated by laminins and cytoskeletal
protein expression [12]; glycogen and glucose regulation and
glycolysis by glycogen synthase, 6-phosphofructo-2-kinase,
and AS160 [13]. Adding to the broad activity of PTEN are
the numerous examples of signaling crosstalk with other
transduction pathways including the Erk, p38, and JNK
mitogen-activated protein kinases [14], the TGF𝛽 and BMP-
associated SMAD pathways [15], the cytokine-mediated Jak-
STAT pathway [16], and IP
3
-mediated calcium signaling [17].
Additionally, interesting recent findings have demonstrated
that PTEN modulates the DNA damage response and repair
via its inhibition of Akt [18]. Because of this diversity, any
mediators that modulate PTEN expression levels or function
have substantial effects on cellular function.
As a critical cellular protein that modulates numerous
processes, it is expected that PTEN plays a major role in
regulating proper development. Yet, PTEN is still primarily
known as a tumor suppressor—the loss of function of which
leads to tumorigenesis.While thismay be true, the last decade
has seen a greatly enhanced understanding of how PTEN
is regulated, particularly as this relates normal growth and
development.This review takes a critical look at the literature
focusing on PTEN regulation, the effects of this regulation
during mammalian development, and how it is regulated by
classical developmental signal transduction mechanisms.
2. PTEN in Developmental Biology
2.1. Early Embryonic Development. PTEN is highly and
ubiquitously expressed throughout developing embryos. It
is expressed as early as the embryonic stem cell stage,
being detectable in embryonic day 3.5 blastocysts in both
extraembryonic and embryonic tissues [19]. PTEN is required
for critical hallmarks of developmental biology including cell
proliferation, growth, death, and migration. In many tissues,
PTEN expression coincideswith the need to repress or induce
proliferation or differentiation in cells, depending on the
tissue need in each location and time point.
At an organismal level, PTEN plays several critical roles
in the early control of the patterning of embryos. First,
PTEN regulation of cell migration is known to control
specification of the anterior-posterior axis of mouse embryos
[20]. Embryos that lack PTEN expression exhibit a notable
set of morphological defects including the failure to correctly
specify the anterior-posterior body axis, improper separation
of body foci, and decreased coordinated migration of cells
along the body axis. PTEN is also necessary for gastrulation
of embryos. PTEN is highly expressed from the midblastula
transition through completion of gastrulation and embryonic
layer separation [21]. In this process, PTEN coordinates cell
cycle elongation and cellular morphogenesis. Embryos lack-
ing PTEN fail to exhibit proper patterning from the blastula
into the germ layers. Lethality of these embryos soon follows.
At the postgastrulation stage, PTEN localization can be found
throughout ectodermal, endodermal, and mesodermal-
derived tissue, including the developmental precursors of the
central nervous system and skin, the liver and gastrointestinal
tract, the urogenital sinus, heart, and skeletal muscle [19, 20].
Anatomy of PTEN systems effects highlighed in Figure 2.
Following the separation of the germ layers, PTEN exerts
dynamic roles throughout development, across numerous
organ systems. The following highlights recent findings.
2.2. Nervous System Development. The high prevalence of
germline PTENmutations inCowden disease and Bannayan-
Riley-Ruvalcaba syndrome, Lhermitte-Duclos syndrome,
autism spectrum disorders, and CNS axon regeneration
demonstrates the significance of PTEN in central nervous
system development and physiology. The brain has been the
most extensively studied organ in the area of PTEN’s role in
developmental biology [22], primarily because of its known
role in the development of gliomas and medulloblastomas.
Identified syndromes associated with germline PTEN in
the CNS include Lhermitte-Duclos disease [23], dysplastic
gangliocytoma [24], gray matter heterotopias [25], mental
retardation [26], autism [27], and seizures [28].
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Figure 2: Precise regulation of PTEN expression, activity, or localization has profound effects on the development of numerous organ systems.
Disruption of PTENat the level of transcription,mRNA stability, protein stability, enzymatic function, or cellular location results in disruption
of these developmental systems.
Cell type-specific mutations of PTEN in animal mod-
els demonstrate developmental phenotypes and resulting
pathology. Glial cell conditional null mutation of the Pten
gene promotes seizures and ataxia early in life in mice
and promotes premature death [28]. Brain size in these
mice increases progressively over time relative to wild-type
littermates, and these mutants develop hydrocephalus and
untoward lateral ventricle growth [28].These animals exhibit
neural dysplasia, thickened internal granule cell layers, and
a progressive increase in neuronal soma size [28]. Further,
mice with oligodendrocyte-specific PTEN deletion exhibit
disruption in the myelination of axons [29]. Importantly,
these murine effects are similar to many common features
associated with PTEN mutations in the human CNS [30].
PTEN deletions in terminally differentiated neurons
result in a number of striking phenotypes. Neuronal-specific
PTEN deletion promotes soma hypertrophy, macroen-
cephaly, and increased axonal outgrowth. This latest find-
ing has led to the hypothesis that PTEN inhibition may
be a potential therapeutic mechanism for inducing axonal
outgrowth in spinal injury patients [31]. These mice also
exhibit increased dendritic spine density, increased caliber
of neuronal projections, and alterations in synaptic trans-
mission [31]. Neurons from these mice exhibit disruption
in Bergmann-glia connections and disorganized cerebellar
architecture [31]. Neuronal-conditional PTEN null mice also
display hyperactivity, signs of anxiety, heightened response
to excitatory stimuli, and disrupted social interaction [32].
Findings from these studies have prompted the hypothesis
that PTEN expression anomalies may be at least in part
responsible for CNS-related disorders in humans.
2.3. Dermal Development. PTEN-mediated signaling has
long been known to be critical for the cytoprotection of
both epithelial cells and melanocytes in the skin. Interest-
ingly, PTEN has recently been shown to be responsible for
regulating the events and timing of epidermal development
[19]. This may have been predictable given the incidence of
benign tumors of the skin in Cowden’s syndrome, a known
PTEN-driven condition. Conditional PTEN deletion induces
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hyperplasia of squamous cells resulting in mounted skin
dermis and papillomas [33]. Additionally, mice with specific
melanocytic PTEN deletion exhibit increased melanocyte
expansion [34].
2.4. Hematopoietic Development. PTEN is necessary for
proper development, lineage fate, and cell function in T cells,
B cells, myeloid cells, NKT cells, and hematopoietic stem cells
(HSCs), as demonstrated by several elegant studies involving
global heterozygous and cell-conditional null PTEN models
[35–40]. It has been known that PTEN (+/−) mice exhibit
lymphoid hyperplasia progressing to T-cell lymphoma com-
plete with large nodal masses [36], and it has now also
been reported that PTEN (+/−) mice develop autoimmune
disorders at an early age due to abrogated PTEN function
[37]. Cell-type T-cell conditional PTEN null mice exhibit
lymphadenopathy, splenomegaly, and hyperplastic enlarged
thymus. Similar to the global PTEN heterozygous mice,
conditional nulls also exhibit autoreactivity evidenced by
increased levels of autoantibodies, expanded T-cell prolifer-
ation, and increased cytokine synthesis and release [38].
Indirect studies show that PTEN-mediated signaling
plays a role in natural killer (NK) cells. Unfortunately,
true cell-selective knockout of PTEN in natural killer (NK)
cells has not been reported due to the lack of a cell-type
specific promoter. However, purified NK cells from PTEN
immune-system null mice exhibit abrogated maturation and
activation [39]. Studies have demonstrated that when these
cells were adoptively transferred intoNK null mice harboring
metastatic melanoma cells, the null cells exhibit strongly
decreased protection from metastases relative to wild-type
NKT cells [39, 40].These results demonstrate that one critical
role of NK cells, namely, tumor targeting, is attenuated
in PTEN null NK cells. In addition, B-cell lineage-specific
PTEN null mice exhibit expanded splenocytes, mesenteric
lymph node cells, and peritoneal cells [41]. B cells deficient
in PTEN display enhanced proliferation upon epitope or
mitogen stimulation, and defective class-switch antibody
recombination resulting in decreased production of IgA and
IgG antibodies and elevated IgM production [41].
Neutrophils isolated from mice with PTEN-null myeloid
lineage cells display increased actin polymerization with
enhanced membrane ruffling, pseudopodia formation, che-
motaxis, and migratory speed [42]. Inflammation in these
mice is associated with vastly increased neutrophil recruit-
ment [42]. Paradoxically, these mice are more susceptible to
infection with Leishmania and exhibit a slower clearance of
infection than wild-type littermates. This disconnect appears
to be due to decreased secretion of tumor necrosis factor
(TNF) by mutant macrophages in these mice [43]. To date,
little else is known about the development of monocytes in
myeloid-specific PTEN null bearing animals.
Deletion of PTEN in murine hematopoietic stem cells in
mice results in a very rapid onset of myeloproliferative disor-
ders and an eventual depletion of the stem cell pool, which,
despite their proliferative nature, results in the loss of the
ability of these stem cells to produce all lineages needed for
proper immune functioning [44]. These myeloproliferative
disorders progressed to acute myeloid leukemia or acute
lymphoblastic leukemia [44]. In a demonstration that Akt-
signaling is downstream of this phenotype, increased HSC
proliferation and even the development of myeloproliferative
disorders and leukemia are all rescued when the mice were
treated with rapamycin [44].
2.5. Visceral OrganDevelopment. There are numerous studies
to date examining the developmental effects of organ-specific
PTEN mutation in mouse models. This review summarizes
the highlights of these studies here.Mammary ducts in tissue-
specific conditional PTEN null mice exhibit loss of differ-
entiation, enhanced growth, excessive side branching, and
precocious budding relative to wild-type controls [45]. These
phenotypes are reported during puberty but also manifest
their effects during mammary expansion during pregnancy.
Notably, mammary gland involution after pregnancywas also
defective [45]. PTEN is important for the normal physiology
of oocytes, as PTEN deficiency in murine oocytes causes
the entire oocyte pool to become activated prematurely [46].
This proves to be critical for fertility and reproduction, as
premature oocyte activation resulted in females having a
maximum of one normal-sized litter before they became
infertile at 12-13 weeks of age [46].
FabpCre-(Ptenflox/flox) mice exhibit a number of inter-
esting phenotypes in the genitourinary system. PTEN dele-
tion occurs in the bladder, ureter, kidney, colon, prostate,
seminal vesicles, and vagina of these mutants [47]. Epithelial
hyperplasia was omnipresent in these animals. As expected,
deletion of PTEN resulted in increased susceptibility to
chemically induced carcinogenesis [48]. Similarly, epithelial
hyperplasia is present in organ specific PTEN knockouts,
followed by intraepithelial neoplasia and ultimately by inva-
sion of the cancer cells as invasive adenocarcinoma [49–51].
Embryonic deletion of PTEN in the lower urinary system
results in a loss of proper differentiation within affected cells
[52], ultimately resulting in loss of proper patterning and
growth control. Based on these data and the collection of
phenotypes observed in PTEN deleted cells and animals, it is
likely that a loss of differentiation of cells plays a master role
in PTEN’s role in organ development.
Recent reports have demonstrated a critical role for PTEN
in the branching morphogenesis and nephron patterning of
developing kidneys. PTEN has been shown to be indispens-
able for developing bud outgrowth, mesenchymal invasion,
and branching morphogenesis in developing kidneys by
mediating the signaling downstream of GDNF/RET receptor
tyrosine kinases [53]. Again, this involves differentiation and
chemotaxis of epithelial cells. More recently, Lindstro¨m et
al. have shown that PTEN sits at the center of nephron
development by integrating signaling from BMP and wnt-
beta-catenin pathways [54]. Disruption of PTEN results in a
loss of coordinated signaling and a loss of proper patterning
of epithelial cells along the axis of the nephron tubule.
Numerous developmental effects of PTEN have been
noted in the gastrointestinal tract. In the colon, PTEN (+/−)
mice develop hamartomatous polyps consistent with dis-
rupted control of differentiation of cells [55]. Further, PTEN
is critical for colon homeostasis involving inflammatory
repair and recovery, processes that reactivate developmental
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signalingmechanisms [56]. In the liver, loss of PTENnot only
increases tumor susceptibility but also altersmetabolism [57].
In addition, hepatomegaly is observed in mice with condi-
tional hepatic PTEN knockout, as the ratio of liver weight
to body weight increased in the mutants when compared
with wild-type controls [57]. Livers harvested from mutant
animals are discolored and show accumulation of triglyc-
erides consistent with steatohepatitis associated with severe
inflammation. Passive diffusion of fatty acids in hepatocytes
was enhanced in PTEN null mice, and PTEN-deficient
hepatocytes exhibit an increased rate of fatty acid synthesis
via induced fatty acid synthase [57]. PTEN-deficient mice
exhibit defects in glucose metabolism, including decreased
fasting plasma glucose levels and reduced serum insulin
levels [58]. Clearance of glucose was accelerated in the
absence of PTEN concurrent with increased liver glycogen
storage.
Pancreatic islet beta-cell specific PTEN-deficient mice
exhibit increases in islet cell numbers, total islet mass,
and an increase in 𝛽-cell progenitor proliferation during
embryonic development and early postnatal life [59]. Adult
PTEN mutant mice were hypoglycemic and were resistant
to streptozotocin-induced diabetes. These mice are signifi-
cantly smaller than controls and have a shorter lifespan. In
some studies, severe hypoglycemia is associated with seizure
activity and premature death before 5 weeks of age [59].
In addition PTEN (+/−) mice exhibit protection against
increased insulin production during reactive oxygen species-
dependent type two diabetes and insulin-resistance upon
aging [60].
PTEN’s role in maintaining glucose balance is not limited
to the liver and pancreas but also involves adipocytes and
myocytes. Inactivation of PTEN specifically in adipocytes
produces no obvious gross morphological effects on the
adipose tissue or adipose tissue mass. However, this mouse
exhibits increased systemic glucose tolerance and insulin sen-
sitivity complete with decreased fasting insulin and resistin
levels [61]. By controlling serum insulin and resistin levels,
PTEN regulates insulin sensitivity and AMP kinase activity
in the liver. Similarly, skeletal and cardiac muscle cell-specific
deletion causes increased systemic glucose tolerance and
insulin sensitivity [62]. Interestingly, however, PTEN loss in
these tissues seems to protect thesemice from streptozotocin-
induced diabetes and hyperglycemia indicating that the
insulin hypersensitivity exhibited in tissue-selective PTEN-
deficient mice allowed them to maintain proper glucose
levels.
PTEN regulates proper lung development. Specific lung
deletion of PTEN during embryogenesis results in impaired
lungmorphogenesis and early postnatal death [61].The lungs
of these neonates exhibit increased epithelial cell proliferation
and decreased alveolar cell differentiation. Adults exhibit
bronchiolar and alveolar epithelial hyperplasia. Mutant mice
exhibit hypertrophy of alveolar cells derived from bron-
chioalveolar stem cells [61]. Predictably, adenocarcinomawas
evident in aged adults. Further study of PTEN’s role in
lung development revealed that PTEN-regulated signaling
mediates lung endodermal morphogenesis coordinate with
the overall developmental process in the lung, and it is central
to the interaction of several signaling pathways including the
TGF beta-SMAD and Nkx2.1 pathways [62].
Normal development of the vascular system is also
dependent on proper PTEN function. PTEN knockout in
endothelial and endocardial cells in mice results in embry-
onic lethality due to increased capillaries and endothelial cell
hypertrophy [63]. These mutant embryos exhibit pericardial
cavity enlargement, leakage of blood into the pericardial
cavity, and enlarged trunk vessels secondary to pericyte and
vascular smooth muscle cell recruitment to blood vessels
[63]. In addition, cardiomyocyte-specific deletion of PTEN
leads to cardiac phenotypes via development of cardiac
hypertrophy and contractile defect [64]. Future studies on
PTEN will hopefully be targeted at assessing injury-related
responses in the cardiovascular system, as deletion of PTEN
in cardiomyocytes has been shown to protect the heart from
maladaptive remodeling upon biomechanical stress.
PTEN regulates developing bone and cartilage by pro-
tecting against overgrowth of the skeletal system. Mice with
deletion of PTEN in osteochondroprogenitor cells exhibit
growth plate dysfunction and overgrowth of the vertebrae
[65]. The bodies of these mice are notably longer than wild-
type controls, demonstrating a critical defect that results
in loss of proper skeletal development. Interestingly, this
increase in length was not due to bone cell proliferation
increases as might have been expected but rather is due to
increased matrix deposition and cellular hypertrophy [65].
In a second model, osteoblast-specific knockdown of PTEN
expression results in increased bone volume and density
[66]. Interestingly, this mutation is associated with improved
intramembranous and late endochondral fracture healing.
This is now an active area of research within the bone
remodeling research field.
While PTEN remains virtually synonymous with cancer
biology, the studies presented here make the importance
of proper PTEN signaling for regulating a wide variety of
developmental processes clearly evident. From regulation of
growth, differentiation, glucose maintenance, and repair and
recovery to gross effects on organ and systems development,
PTEN is a protein with vast consequence in the field of
developmental biology, and the signaling affected by its
expression is expansive.The role PTEN plays in development
has clear correlates to human disease. Further, PTEN’s effects
on development acquire greater importance when the role
that developmental signaling plays in cancer growth and
progression is considered.Therefore, an extensive knowledge
of how PTEN is regulated by developmental signaling, apart
from somatic or genetic mutation, is required for complete
understanding of PTEN’s role in these important physiologi-
cal processes.
3. PTEN Regulation as Part of
Developmental Signaling
3.1. Intrinsic and Extrinsic PTEN Regulation. Most studies
evaluating the role of PTEN in human diseases have been
centered uponmutation in PTEN itself, andmost of this work
is done in its relationship to cancer initiation and progression.
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Figure 3: Summary of regulation mechanisms for PTEN critical for its action in developmental biology. PTEN transcription is regulated
by TGF𝛽, BMP, Hh, NOTCH, and cytokine signaling in cells during development. miRNAs and ceRNAs regulate PTEN message stability.
Phosphorylation or acetylation by then can regulate PTEN’s protein stability, enzymatic activity, and cellular localization in a positive or
negative manner. All told, the regulation of PTEN is complex and precise during development, and perturbations in this paradigm have
profound effects.
There is no question that mutations of PTEN play a critical
role in this regard. Studies over the last decade, however,
have discovered a tremendous diversity in the regulation
of PTEN expression and found that PTEN is tightly con-
trolled both transcriptionally and posttranscriptionally [67].
Recent studies to date have implicated microRNAs in PTEN
suppression [68], and the enzymatic phosphatase activity
of PTEN is also regulated posttranslationally via phospho-
rylation, ubiquitination, or oxidation [69, 70]. This section
highlights the multifaceted mechanisms of PTEN regulation,
supported by the rapidly expanding literature on PTEN’s role
in growth and patterning of tissues during development. In
addition, special emphasis is given tomediators and pathways
involved in development including insulin-like growth factor,
transforming growth factor, bone morphogenetic proteins,
NOTCH, forkhead transcription factors (Fox), and others.
PTEN’s complex regulation at the levels of transcription,
mRNA stability, posttranslational modifications, andmiRNA
levels has become a critical series of mechanisms deserving a
comprehensive review (for an overview, see Figure 3).
3.2. Developmental Signaling Regulating PTEN Expression
and Action. The regulation of PTEN expression occurs at
transcriptional, posttranscriptional, posttranslational, and
protein-protein interaction levels [71]. PTEN’s function is
further controlled by its cellular location. In this section,
we highlight developmental pathways involved in regulating
PTEN expression at all these regulation points and make
special reference to connections between signal transduction
and development.
3.2.1. Developmental Pathways in PTEN Gene Expression.
One critical aspect of PTEN’s regulation during development
begins at the transcriptional level. To date, PTEN expres-
sion has been found to be regulated at the transcriptional
level by pathways involving p53, PPAR𝛾, Egr-1, NF-𝜅B,
and SMADs, and this regulation affects the development
of proper immune function, the vasculature, the nervous
system, the gastrointestinal system, and the airways [63,
72, 73]. While PTEN is constitutively expressed in many
normal adult tissues, PTEN expression is altered dramat-
ically through the course of development and in patho-
logical settings, and a primary source of this regulation
comes from bona fide developmental regulators. In addition,
suppressors of cytokine signaling (SOCS) and SNAIL also
induce PTEN and act by countering the growth-promoting
actions of cytokines and growth factors in development
and repair and recovery [74]. This mechanism has been
clearly demonstrated in axonal outgrowth during neuron
development and regeneration [74]. While the physiological
ramifications of this regulation remain unsolved, mediators
that slow or inhibit cell proliferation are often involved in
inducing this protein. Developmental mediators including
NOTCH, transforming growth factor beta (TGF𝛽), bone
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morphogenetic proteins (BMPs), and hedgehogs (Hhs) all
participate as players in external PTEN regulation [75–
78], regulating such processes as proliferation and targeted
epithelial budding and outgrowth of visceral organs [76, 77],
and outgrowth in neurons [75]. As the direction of cell growth
and differentiation balances on the fulcrum between the
proliferative and differentiating actions of these mediators,
their regulation to induce or repress PTEN expression is
a critical aspect of their actions during development. The
critical developmental mediator TGF𝛽 contains both growth
promoting and inhibiting differentiation qualities, and TGF𝛽
induces PTEN during differentiation when growth is slowed
and inhibits its expression during proliferation. In addition,
the developmental regulator DJ-1 was recently identified as
a novel negative regulator of PTEN by a genetic screen in
Drosophila [79]. PTEN is also regulated through epigenetic
silencing by methylation of the PTEN promoter [80, 81]. An
interesting zinc-finger transcription factor, sal-like protein 4
(SALL4), has been discovered as a critical negative regulator
of PTEN transcription by recruiting an epigenetic repressor
complex involving anATPase and a histone deacetylase to the
PTENpromoter [80]. SALL4 plays a critical role in regulating
development by modulating self-renewal in stem cells, and
its function appears to at least partly involve methylation of
the PTENpromoter andmodulation of its transcription.Data
on this mechanism are still limited, but to date this process
has been shown to regulate kidney patterning during devel-
opment as well as leukemogenesis [80]. Current research in
the area of PTEN transcriptional regulation continues to be
dynamic, and more novel regulation patterns are likely to be
discovered in the near future.
3.2.2. PTEN Regulation by Posttranscriptional Regulation.
Recent studies have identified several interesting develop-
mentally expressed miRNAs that regulate PTEN mRNA
message stability and translatability [82]. These miRNAs
typically downregulate PTEN mRNA levels by targeting it
for degradation and include miR-17, miR-19, and miR-21 [83–
85]. While several examples of miR-17 and miR-19-mediated
PTENRNA levels have been reported in the cancer literature,
miR-21 has been described to play a critical role in repair
and recovery, a developmental signaling-related process.
miRNAs regulate this mechanism by modulating PTEN
RNA stability and ultimately downstream Akt signaling. For
example, in the pancreas, miR-21 regulates injury repair in
diabetic models by targeting PTEN RNA for degradation.
Inhibition of miR-21 results in autophagy in this model in
a manner dependent on PTEN degradation [85]. In another
example of novel miR-related PTEN regulation, the PTEN
pseudogene 1 (PTENP1) acts as a decoy for PTEN-targeting
miRNAs and thereby regulates PTEN expression by coding-
independent activity through sequestering these miRNAs
and effectively inhibiting their effects on PTEN expression
[86]. Additionally, combined bioinformatic and experimental
approaches have identified ceRNA transcripts that control
PTEN expression by sequestering PTEN-targeting miRNAs
during development of both prostate and skin [87]. Because
this type of PTEN regulation, and indeed this field of gene
regulation in general, is in its infancy, we are only beginning
to understand the PTEN regulation by coding and noncoding
ceRNAs. Still, this novel work provides a platform for further
studies investigating posttranscriptional regulation patterns
of PTEN expression in both developmental biology and
disease conditions.
3.2.3. PTENRegulation by PosttranslationalMechanisms. The
protein stability and enzyme activity of PTEN are regulated
in a number of ways at the posttranslational level. First,
PTEN is phosphorylated in its C-terminal tail at Ser380,
Thr382, Thr383, and Ser385, and this functions to inhibit
the critical PTEN phosphatase activity, thereby promoting
growth in prostate and kidney cells [88]. However, these
phosphorylations also stabilize the PTEN protein by dis-
suading ubiquitination. While this may seem like a cellular
disconnect, this paradoxical phenomenon is explained by the
finding that this closed, more stable PTEN conformation is
prevented from associating with membranes and therefore
is geographically separated from its substrates [88]. PTEN
can also be activated by phosphorylation; in particular, the
C2 domain of PTEN is phosphorylated at Ser229 andThr321
by RHOA-associated protein kinase (ROCK) [89], a phos-
phorylation that results in its association with membranes
and phosphoinositide substrates, affecting differentiation in
leukocytes. PTEN is further phosphorylated at Tyr336 by the
Tyr protein kinase RAK, and this phosphorylation results
in its stabilization [90]. Loss of this activity has the effect
of promoting breast cell proliferation and migration. Finally,
PTEN is also phosphorylated at Ser370 and Thr366 by CK2
and GSK3𝛽 [91, 92], respectively; however, the consequences
of this phosphorylation are unclear. The likely extensive
signaling networks that regulate these widespread phospho-
rylations in PTEN are not fully studied, but the TGF/BMP-
SMADdevelopmental pathways are known to regulate PTEN
phosphorylation [93, 94]. Given the widespread application
of SMAD signaling to developmental biology, the presence of
SMAD-regulated PTEN phosphorylation is a critical aspect
of developmental regulation in cells.
PTEN enzymatic activity is also regulated posttrans-
lationally by acetylation [70, 95–97]. PTEN is acetylated
at Lys125–Lys128 by p300/CREB-binding protein- (CBP-)
associated factor (PCAF) and at Lys402 by CBP itself [95].
Acetylation at these residues inhibits PTEN’s function as a
phosphatase and has been shown to promote the growth
of prostate epithelial cells and glial cells [95]. In addition,
the deacetylase Sirtuin 1 (SIRT1) is involved in excluding
PTEN from the nucleus and therefore preventing its newly
characterized nuclear functions [96].
3.2.4. PTEN Regulation by Protein-Protein Interactions. The
conformation, stability, and subcellular distribution of PTEN
is regulated by critical interactions with other proteins within
cells, and these proteins are known to be critical for proper
development of a number of organ systems. The guanylate
kinase inverted 2 (MAGI2) and 𝛽-arrestins cooperate to
enhance PTEN activity [98, 99]. MAGI2 phosphorylates
PTEN on threonine residues at positions 382 and 383 of
PTEN’s carboxy terminus, allowing recruitment to cell-cell
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junctions [98]. Mutations to these residues prevent PTEN
recruitment. Upon recruitment, 𝛽-arrestins modulate PTEN
activity by direct binding to the C2 domain and modulating
its protein phosphatase activity, including that at the level
of small GTPases including RhoA/ROCK [99]. In addi-
tion, Myosin V regulates PTEN’s movement to and from
the plasma membrane, and this function is required for
PTEN to access its phosphoinositide substrates [100] and
for disrupting the proper regulation of neuronal cell size.
The p85 regulatory subunit of the PI
3
kinase enzyme itself
interacts with PTEN in a novel mechanism of repressing the
PI
3
K–AKT pathway [101] independent of PTEN’s action as a
phosphatase. It is therefore proposed that p85 regulates the
PI
3
K–AKT pathway bidirectionally both through its binding
to catalytic p110 subunit resulting in the generation of phos-
phoinositides and by binding PTEN, leading to repression.
This work proposes a novel signaling model for PTEN-p85
association, in which p85𝛼 preferentially binds and stabilizes
p110 preferentially when p85𝛼 levels are low, but excess p85𝛼
binds to and positively regulates PTEN phosphatase activity
when p110 is saturated. Therefore, sustained activation of
PI3K signaling and activated p110-p85 complexing is modu-
lated homeostatically by this mechanism.
A fascinating group of recent studies have utilized
proteomic library screens to identify further novel PTEN
interacting proteins. First, the Na+/H+ exchanger regulatory
factor (NHERF) binds to and recruits PTEN to the platelet-
derived growth factor receptor (PDGFR). This represents
another action that restricts PI
3
K–AKT pathway activation,
independent of phosphatase activity [102]. This has the effect
of inhibiting PDGF-induced cytoskeletal rearrangements and
chemotactic migration of developing neurons. In addition,
the mammalian disks large homologue 1 (DLG1), MAGI-
2, and MAST205 proteins directly interact with PTEN
and enhance PTEN stability and activity [103]. Further,
neuregulin 1 (NRG1) has been shown to interact with both
DLG1 and PTEN in a stable complex that has the effect of
regulating myelin sheath thickness in developing mouse sci-
atic nerves [104]. Additional but less-characterized protein-
protein interactions that modulate PTEN function include
the PIP
3
-dependent RAC exchanger factor 2a (PREX2a)
[105], shank-interacting protein-like 1 (SIPL1) [106], and 𝛼-
mannosidase 2C1 (MAN2C1) [107].
3.2.5. PTEN-Controlled Signal Transduction during Develop-
ment. PTEN is critically important in regulating signaling
pathways involved in cell growth and animal development.
Through its well-characterized function as a phosphatase
of PIP
3
, PTEN modulates a network of mitogen-activated
signals transduced through PI
3
K–Akt signaling. This pri-
mary action of PTEN has tremendous impact on cell growth,
cell migration, cell death, and cell differentiation—cellular
processes that are all hallmarks of proper growth and
patterning during development. The active phosphorylated
PIP
3
activates several signaling molecules including the
phosphatidylinositol-dependent kinases (PDKs), followed by
Akt, S6 kinase, and mTOR. Beyond this, AKT’s targets
include the apoptotic factor BAD, activator and executioner
caspases, glycogen synthase kinase-3 (GSK-3), MDM2, p21
and p27, forkhead transcription factors (FOXOs), and nuclear
receptors including the androgen and estrogen receptors
[108]. Akt-mediated phosphorylation of these molecules
causes activation, translocation, and increased stability.
The PTEN/PI
3
kinase/AKT signaling cascade crosstalks
to several key signal transduction pathways that are critical
to developmental biology. This includes the abovementioned
TGF-𝛽/SMAD pathway and the Wnt/𝛽-catenin pathway
[109]. The TGF-𝛽/SMAD pathway is one of the most seminal
pathways in developmental biology, and PTEN modulates
TGF𝛽/SMAD signaling by reversing Akt-mediated phospho-
rylation of SMAD3, the critical signaling intermediate of
TGF𝛽/SMAD signaling [110]. Similarly, the Wnt signaling
pathway is indispensable for properly regulated development,
cellular proliferation, and differentiation [111]. PTEN regu-
lates this pathway by reversing AKT kinase phosphorylation
and inhibition of GSK-3𝛽, resulting in 𝛽-catenin nuclear
translocation and activation. Finally, recent studies demon-
strate that PTEN regulates the expression and action of the
homeobox genes NKX3.1 and hepatic nuclear factor [112],
proteins that are critical to organ development.
3.2.6. PTEN-Regulated Stem Cell Activities. The scientific
literature in the field of tissue stem or stem-like “progen-
itor” cells and their role in tissue development, growth,
recovery and repair has become beyond extensive in recent
years. Expansion of stem/progenitor cells is a hallmark of
growth and patterning during development, and regulation
of these cells, including their proliferation, maintenance,
and differentiation, is a critical factor of developmental
regulation. Because of this, a review of the current liter-
ature on PTEN’s role in stem and tissue progenitor cells
is warranted in this review. PTEN plays an important role
in regulating the homeostasis of stem/progenitor cells in
multiple tissues. Interestingly, PTEN regulates both self-
renewal and proliferation, but paradoxically it also plays
a role in stem cell exhaustion. For example, the FOXO
family of transcription factors controls stem cell proliferation
and survival in hematopoietic stem cells [113], and PTEN
signaling is a critical modulator of FOXO activity. FOXO3A-
deficient HSCs exhibit increased proliferation rate, decreased
quiescence, and a reduced ability to repopulate bone marrow
after transplantation into recipient mice. Additionally, the
previously mentioned Wnt/𝛽-catenin signaling pathway is
critical for HSC self-renewal, and its activation is well known
to be modulated by PTEN. Interestingly, PTEN loss and AKT
activation in HSCs lead to a moderate increase in the level
of unphosphorylated 𝛽-catenin, but this is not sufficient to
maintain Pten-null HSC self-renewal [114]. Finally, NOTCH
signaling plays a key role in regulating neural stem cell
expansion [115] and, as stated previously, NOTCH pathway
activation leads to reduced PTEN expression in neural and
hematopoietic stem cells.
4. Conclusions
PTEN acts as the key endogenous negative modulator
of phosphoinositide signaling in mammalian cells, and
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therefore its role in normal cell homeostasis, proliferation,
apoptosis, and many additional components of cell biology
is extensive. Because PTEN regulates cancer progression,
much of what has been studied regarding PTEN relates to
tumorigenesis and tumor growth. While this is warranted
because of the relevance of cancer to humanhealth, PTENhas
substantial but underappreciated effects in normal tissue and
organ development, immune system development and reg-
ulation, axonal regeneration, glucose regulation, and benign
growth disorders. PTEN is often dogmatically thought of
as a constitutive protein that exhibits lost activity during
diseases, butwhat is underappreciated is that PTENhas a very
complex regulation network that involves signaling path-
ways that regulate PTEN transcription, transcript stability,
posttranslationalmodifications, protein-protein interactions,
and cellular location. PTEN then in turn regulates numerous
developmental signaling networks that are critical to devel-
opment and adult tissue maintenance.
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